104 related articles for article (PubMed ID: 28368402)
1. Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.
Cesarini V; Guida E; Todaro F; Di Agostino S; Tassinari V; Nicolis S; Favaro R; Caporali S; Lacal PM; Botti E; Costanzo A; Rossi P; Jannini EA; Dolci S
Oncogene; 2017 Aug; 36(31):4508-4515. PubMed ID: 28368402
[TBL] [Abstract][Full Text] [Related]
2. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
[TBL] [Abstract][Full Text] [Related]
3. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
4. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M
J Clin Invest; 2013 Dec; 123(12):5104-18. PubMed ID: 24200692
[TBL] [Abstract][Full Text] [Related]
5. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
6. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
[TBL] [Abstract][Full Text] [Related]
7. Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma.
Xie X; Koh JY; Price S; White E; Mehnert JM
Cancer Discov; 2015 Apr; 5(4):410-23. PubMed ID: 25673642
[TBL] [Abstract][Full Text] [Related]
8. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
9. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
10. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
12. Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma.
Scortegagna M; Ruller C; Feng Y; Lazova R; Kluger H; Li JL; De SK; Rickert R; Pellecchia M; Bosenberg M; Ronai ZA
Oncogene; 2014 Aug; 33(34):4330-9. PubMed ID: 24037523
[TBL] [Abstract][Full Text] [Related]
13. p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells.
Pietrobono S; De Paolo R; Mangiameli D; Marranci A; Battisti I; Franchin C; Arrigoni G; Melisi D; Poliseno L; Stecca B
J Biol Chem; 2022 Sep; 298(9):102353. PubMed ID: 35944584
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
15.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
16. Sox2 is dispensable for primary melanoma and metastasis formation.
Schaefer SM; Segalada C; Cheng PF; Bonalli M; Parfejevs V; Levesque MP; Dummer R; Nicolis SK; Sommer L
Oncogene; 2017 Aug; 36(31):4516-4524. PubMed ID: 28368416
[TBL] [Abstract][Full Text] [Related]
17. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
18. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib in melanoma.
Shaw HM; Nathan PD
Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
[TBL] [Abstract][Full Text] [Related]
20. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]